Can I Take Alpha-Lipoic Acid with Repatha (Evolocumab)?

Why This Combination Raises Questions

Repatha (evolocumab) is a PCSK9 inhibitor prescribed for familial hypercholesterolemia and established atherosclerotic cardiovascular disease (ASCVD). Alpha-lipoic acid is a popular antioxidant supplement with emerging data on lipid metabolism and neuroprotection. Patients prescribed Repatha often ask whether adding ALA could cause problems or, conversely, provide additive cardiovascular benefit.

How Evolocumab Works

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, the drug prevents degradation of LDL receptors on hepatocytes, allowing more LDL-C clearance from the bloodstream. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% compared with placebo and lowered major cardiovascular events by 15% over a median follow-up of 2.2 years [1]. The drug is administered as a 140 mg subcutaneous injection every two weeks or 420 mg once monthly.

How Alpha-Lipoic Acid Works

ALA is a dithiol compound synthesized endogenously in mitochondria. It functions as a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Supplemental ALA acts as a potent antioxidant, regenerates other antioxidants (vitamins C and E, glutathione), and activates AMP-activated protein kinase (AMPK) [2]. This AMPK activation is the reason ALA has insulin-sensitizing and mild lipid-modifying properties. A 2018 meta-analysis of 24 randomized controlled trials (N=1,272) found that ALA supplementation reduced total cholesterol by 8.8 mg/dL, LDL-C by 7.9 mg/dL, and triglycerides by 11.8 mg/dL [3].

Interaction Analysis: Pharmacokinetic vs. Pharmacodynamic

The short answer is that these two agents do not share metabolic pathways. But "no interaction" requires more nuance than a single sentence.

No Pharmacokinetic Overlap

Evolocumab is a monoclonal antibody. It does not undergo hepatic cytochrome P450 metabolism. Instead, it is cleared through target-mediated disposition (binding PCSK9) and non-specific proteolytic degradation, the same way the body breaks down other endogenous proteins [4]. ALA, by contrast, is absorbed in the gut, undergoes first-pass hepatic metabolism via beta-oxidation and S-methylation, and is excreted renally. Because evolocumab bypasses the liver's drug-metabolizing enzymes entirely, ALA cannot inhibit or induce its clearance. No published case reports, pharmacovigilance signals, or interaction database entries document a pharmacokinetic conflict between the two.

Pharmacodynamic Considerations

Where some overlap exists is in downstream effects on lipid levels. Both agents lower LDL-C, though by wildly different magnitudes: evolocumab by roughly 60%, ALA by about 5 to 10 mg/dL. This is additive, not antagonistic, and presents no clinical hazard. If anything, the small additional LDL-C reduction from ALA aligns with the treatment goal.

The more relevant pharmacodynamic concern involves blood glucose. ALA enhances insulin signaling through AMPK activation and GLUT4 translocation, which can lower fasting blood glucose by 10 to 15 mg/dL in patients with type 2 diabetes [5]. Evolocumab itself does not affect glucose homeostasis. The concern arises indirectly: many patients on Repatha also take metformin, sulfonylureas, or insulin for concurrent metabolic disease. Adding ALA to that regimen could increase hypoglycemic risk. This is not an evolocumab-ALA interaction per se. It is an ALA-antidiabetic drug interaction in a patient who happens to also take evolocumab.

The Thyroid Hormone Consideration

ALA has been shown to reduce circulating levels of triiodothyronine (T3) and thyroxine (T4) in animal studies, and limited human data suggests a similar effect. A study published in Hormone and Metabolic Research found that 600 mg of oral ALA daily for four weeks lowered total T3 and free T4 in healthy subjects, likely by inhibiting peripheral 5'-deiodinase activity [6].

Why This Matters for Repatha Patients

Hypothyroidism itself raises LDL-C. Untreated or under-treated thyroid disease can blunt the effectiveness of any lipid-lowering therapy, including PCSK9 inhibitors. If ALA suppresses thyroid hormone conversion enough to shift TSH upward, LDL-C could rise modestly, partially offsetting Repatha's benefit. The clinical significance in most patients is small. But patients already on levothyroxine should separate ALA dosing from thyroid medication by at least two hours and have TSH checked 6 to 8 weeks after starting ALA.

Who Needs Extra Monitoring

Patients with subclinical hypothyroidism, Hashimoto's thyroiditis, or those on a stable levothyroxine dose are the most relevant population. For these individuals, even a 10 to 15% dip in peripheral T4-to-T3 conversion could push them into symptomatic territory: fatigue, weight gain, rising LDL-C. A simple TSH recheck resolves the question.

Monitoring Recommendations When Using Both

Routine lab monitoring for patients on evolocumab already includes periodic lipid panels. Adding ALA does not demand a fundamentally different monitoring strategy, but a few additions are reasonable.

Lipid Panel

Recheck a fasting lipid panel 4 to 8 weeks after adding ALA to confirm LDL-C remains at target. The FOURIER trial set a median on-treatment LDL-C of 30 mg/dL with evolocumab [1]. ALA should not meaningfully shift this number, but confirming stability is good practice.

Fasting Glucose and HbA1c

For patients with type 2 diabetes or prediabetes, check fasting glucose and HbA1c at baseline and again at 8 to 12 weeks. A meta-analysis of 20 RCTs (N=1,245) demonstrated that ALA at 300 to 1,800 mg daily reduced fasting glucose by a weighted mean of 9.5 mg/dL and HbA1c by 0.38% [5]. That effect size is clinically meaningful if the patient is already near hypoglycemic thresholds on existing diabetes medications.

Thyroid Function

Check TSH at baseline before adding ALA, then recheck at 6 to 8 weeks. This is especially important for patients on levothyroxine or those with borderline thyroid function. The American Thyroid Association recommends TSH monitoring 4 to 8 weeks after any medication or supplement change that could affect thyroid hormone levels [7].

Injection Site Monitoring

This is unrelated to ALA but worth noting: evolocumab injection-site reactions occurred in 3.2% of patients in the FOURIER trial [1]. ALA does not influence this rate. Standard injection-site rotation advice applies.

Dose-Separation Guidance

Because evolocumab is injected subcutaneously every 2 or 4 weeks and ALA is taken orally (usually daily), the two agents never physically compete for absorption. No dose-separation window between them is necessary.

When Separation Does Matter

The separation issue applies to ALA and other oral medications in the patient's regimen. ALA can chelate metal ions and may reduce absorption of iron, magnesium, or calcium supplements if taken simultaneously. For patients on levothyroxine, the two-hour separation rule applies because ALA's effect on deiodinase activity and potential chelation of trace minerals could alter thyroid hormone bioavailability.

A practical schedule for a patient on evolocumab, levothyroxine, and ALA:

• Morning, empty stomach: levothyroxine
• Two hours later, with breakfast: ALA (300 to 600 mg)
• Evolocumab injection: any time on scheduled injection day, independent of ALA timing

What the Evidence Says About ALA and Cardiovascular Outcomes

Patients taking Repatha for ASCVD risk reduction may wonder whether ALA adds cardiovascular protection beyond its modest lipid effects.

Oxidative Stress and Endothelial Function

ALA reduces oxidative stress markers including malondialdehyde and increases endothelial nitric oxide synthase (eNOS) activity. A randomized trial of 58 patients with metabolic syndrome found that 300 mg of ALA daily for 8 weeks improved flow-mediated dilation by 44% compared with placebo [8]. Endothelial dysfunction is an early driver of atherosclerosis, so this mechanism is at least theoretically complementary to LDL-C lowering with evolocumab.

No Hard Outcome Data for ALA

No large cardiovascular outcomes trial has tested ALA as a primary intervention for ASCVD. The available evidence is limited to surrogate endpoints: lipid levels, oxidative stress markers, endothelial function, and glycemic parameters. The FOURIER trial demonstrated hard outcomes (myocardial infarction, stroke, cardiovascular death) for evolocumab [1]. ALA has no equivalent evidence base. Patients should not view ALA as a substitute for, or equivalent complement to, their prescribed PCSK9 inhibitor.

The NATHAN 1 Trial Context

The largest ALA trial for a clinical endpoint is NATHAN 1 (N=460), which tested 600 mg of ALA daily for 4 years in diabetic neuropathy [9]. The trial showed improvement in neuropathy impairment scores but was not designed to capture cardiovascular events. It does, however, confirm the long-term safety of 600 mg daily ALA dosing, which is reassuring for patients planning to use ALA alongside chronic Repatha therapy.

What to Do If You Are Already Taking Both

Many patients start ALA on their own before discussing it with their prescriber. If you are already taking both evolocumab and ALA without apparent problems, that is not surprising given the absence of direct interaction.

Steps to Formalize the Combination

1. Inform your prescribing physician or cardiologist that you are taking ALA, including the exact dose and brand.
2. Request a lipid panel, fasting glucose (if diabetic), and TSH at your next visit.
3. Continue ALA at your current dose unless labs reveal an unexpected shift.
4. If your LDL-C has risen above target, investigate thyroid function before attributing the change to ALA.

When to Stop ALA

Discontinue ALA and contact your physician if you experience symptomatic hypoglycemia (blood glucose <70 mg/dL with shakiness, sweating, confusion), new symptoms of hypothyroidism (unexplained fatigue, cold intolerance, constipation, weight gain), or any allergic reaction such as rash, itching, or difficulty breathing.

Special Populations

Patients with Chronic Kidney Disease

ALA is renally excreted. Patients with eGFR <30 mL/min/1.73m² should use lower ALA doses (no more than 300 mg daily) and have renal function monitored. Evolocumab does not require dose adjustment in renal impairment because monoclonal antibodies are cleared by proteolysis, not renal filtration [4].

Older Adults

Patients over 75 were underrepresented in both FOURIER and ALA trials. The FOURIER subgroup analysis showed consistent LDL-C lowering in elderly patients, though the absolute cardiovascular benefit was smaller [10]. ALA's glucose-lowering effect may be more pronounced in older adults with reduced hepatic clearance, increasing hypoglycemic risk if they are also on sulfonylureas or insulin.

Pregnant or Breastfeeding Patients

Evolocumab is classified as a monoclonal antibody that crosses the placenta, and its use during pregnancy is not recommended. ALA lacks adequate human pregnancy safety data. Neither agent should be used during pregnancy or lactation without explicit physician guidance.

The Bottom Line on Safety

The combination of evolocumab and alpha-lipoic acid carries no documented direct interaction. The two agents operate through entirely separate mechanisms and metabolic pathways. The practical concerns are indirect: ALA's effects on blood glucose (relevant if you take diabetes medications) and thyroid hormone conversion (relevant if you have thyroid disease or take levothyroxine). A baseline TSH, a fasting glucose check, and a follow-up lipid panel at 4 to 8 weeks after starting ALA provide sufficient safety surveillance for most patients on Repatha.